C07C323/67

Histone acetyltransferase activators and uses thereof

The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.

Histone acetyltransferase activators and uses thereof

The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.

HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF

The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.

HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF

The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.

SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

PRE-ASSEMBLED, PROTECTED, CHEMICALLY STABLE, CHEMOSELECTIVE LINKERS
20190359566 · 2019-11-28 ·

Molecules compounds are provided having the structure in Formula I, or a salt thereof, wherein n1 is independently 0, 1, 2, or 3; n2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; n.sup.3 is from 0, 1, 2, or 3; n.sup.4 is 0 or 1; and n.sup.5 is 0, 1, 2, or 3; and wherein X is O, N, or S; Y, Z, XX, and YY are the same or different and are independently O or S; ZZ comprises nitrogen, oxygen, sulfur, or selenium; and wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12 are as described herein. Methods are also provided for the synthesis of and use of the provided molecules in applications for diagnostic testing.

PRE-ASSEMBLED, PROTECTED, CHEMICALLY STABLE, CHEMOSELECTIVE LINKERS
20190359566 · 2019-11-28 ·

Molecules compounds are provided having the structure in Formula I, or a salt thereof, wherein n1 is independently 0, 1, 2, or 3; n2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; n.sup.3 is from 0, 1, 2, or 3; n.sup.4 is 0 or 1; and n.sup.5 is 0, 1, 2, or 3; and wherein X is O, N, or S; Y, Z, XX, and YY are the same or different and are independently O or S; ZZ comprises nitrogen, oxygen, sulfur, or selenium; and wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12 are as described herein. Methods are also provided for the synthesis of and use of the provided molecules in applications for diagnostic testing.